PILOT STUDY OF INTRAVITREAL INJECTION OF DICLOFENAC FOR TREATMENT OF MACULAR EDEMA OF VARIOUS ETIOLOGIES

• DOI: 10.1097/iae.0b013e3181bdfa43
• Publication Date: 2010-02-27T06:03:35Z
• Authors: MASOUD SOHEILIAN; SAEED KARIMI; ALIREZA RAMEZANI; GHOLAM A. PEYMAN
• Keywords: Aged, 80 and over; Male; Diclofenac; Anti-Inflammatory Agents, Non-Steroidal; Visual Acuity; Pilot Projects; Middle Aged; Macular Edema; Retina; Injections; 3. Good health; Vitreous Body; 03 medical and health sciences; 0302 clinical medicine; Electroretinography; Humans; Female; Prospective Studies; Fluorescein Angiography; Aged

The purpose of this study was to evaluate the effect of a single dose of intravitreal diclofenac, a potent nonsteroidal antiinflammatory drug, on visual acuity and central macular thickness in patients with macular edema of various etiologies.In this prospective noncomparative case series, 10 eyes of 10 patients with clinically significant diabetic macular edema (n = 5), neovascular age-related macular degeneration (n = 2), pseudophakic cystoid macular edema (n = 1), macular edema secondary to old branch retinal vein occlusion (n = 1), and cystoid macular edema secondary to chronic intermediate uveitis (n = 1) received 500 microg/0.1 mL of intravitreal diclofenac. The primary outcome measure was change in visual acuity.After 2 weeks, visual acuity improved in 3 (30%) eyes (P = 0.78), did not change in 3 (30%) eyes, and decreased in 3 (30%) eyes. After 4 weeks, improvement of best-corrected visual acuity occurred in 5 (50%) eyes (P = 0.07), but in 3 eyes (30%), best-corrected visual acuity did not change, and in 1 eye (10%), visual acuity decreased. After 8 weeks, visual acuity improved in 7 (70%) eyes (P = 0.019), got worse in 1 eye (10%), and did not change in 2 eyes (20%). Central macular thickness did not decrease significantly at 8 weeks. On the basis of electroretinography, no significant changes in the amplitude of a-wave or b-wave in relation to baseline were noticed in any eye.Up to 8 weeks, intravitreal diclofenac treatment of eyes with macular edema of various etiologies yielded prominent improvement in visual acuity but was not associated with a significant decrease in central macular thickness. No toxic effect of intravitreal diclofenac was observed.